1789 TT

ScinoPharm

March 17, 2022

ScinoPharm

Disclaimer

This material has been prepared by ScinoPharm Taiwan, Ltd. ("ScinoPharm").

Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. ScinoPharm is under no obligation to update or keep current the information contained herein. The **information contained** in this presentation **is** ScinoPharm's **confidential** information.

Any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it is prohibited and may be unlawful.

No representation or warranty, express or implied, is or **will be made** in or in relation to, and no responsibility or liability is or will be accepted by the Company **as to**, the **accuracy or completeness** of this material and any liability therefore is hereby expressly disclaimed.

Statements made in this material include forward-looking statements, which include, without limitation, statements about the issues, plans and expectations of ScinoPharm. Without limiting the foregoing, statements including the words "believes", "anticipates", "plans", "expects" and similar expressions are also forward-looking statements. Forward-looking statements reflect, among other things, management's plans and objectives for future operations, current views with respect to future events and future economic performances and projections of various financial items. **These forward-looking statements involve known and unknown risks**, uncertainties and other factors **which may cause actual results to differ materially from those implied** by such forward-looking statements.

Table of Content

- Business Overview
- Business Update
- 2022 Product Approval Plan
- Financial Performance

Business Overview

I. Current Businesses Development on Balance

- **Persistent Covid-19 epidemic continues to impact supply chain. Flexible and strategic resilience becomes an essential competency.**
- **Three core businesses made progress on drug approval and product launch, demonstrating execution capability in the long run.**
- **2021 sales in USD decreased 5.6% yoy. Consolidated sales were NTD 2,762 million, down 10.4% yoy, partially affected by NTD appreciation; NPAT was NTD 243 million, down NTD 39 million, with NPAT margin 8.8%**

II. Actively Develope Injectable Business

- **Injectable plant was certified by TFDA in 2021;**
  US FDA's 1st on-site inspection is scheduled in Mar. 2022.
- **In-house prefilled-syringe product and liquid solution products were submitted to FDA for ANDA. Vial line and Cartridge line are deployed for production.**
- **Concentrate resources on complex injectables and peptide products.**
- **Open to collaborations and alliances with flexibility to explore business opportunities.**

III. Dual-Track Model: In-house Products and CDMO Business

- **In-house Products**
  - Focus on core products; continue to expand new markets and new customers.
  - Leverage production advantage of Taiwan and Changshu sites for mutual support.
- **CDMO Businesses**
  - Strengthen manufacturing and R&D capacities to support customer needs.
  - Support customer product launches for sales momentum.

Business Update

Strengthen Core API Portfolio

Generic API Products



2021 Approved Generic API Products

Product	Region	Indication	Brand Marketer
Fondaparinux Sodium	CN	Anti-thrombotic	Mylan
Sodium Phenylbutyrate	CN	Urea cycle disorders	Horizon Therapeutics
Letrozole	CN	Breast cancer	Novartis
Pemetrexed Disodium $7H_2O$ CEP*	EU	Non-small cell lung cancer	Eli Lilly

* Collaborative project for drug product development

ScinoPharm

Expand CDMO Business

Develop peptide business

Expand production and R&D capabilities

CDMO Business Status



Data as of 2022/02/28

2021 Approved CDMO API Products

Product	Region	Indication	Brand Marketer
Donafenib*	CN	Cancer	Suzhou Zelgen
Camcevi**	US	Cancer	Foresee

* Summited to NMPA in Oct. 2021 for new indication (Thyroid cancer)

** MAA review in progress; clinical trial application accepted by China NMPA for substantial review in year-end of 2021

ScinoPharm

Advancing to Injectables

Injectables Products

- Focus on complex injectables, peptide & combination products
- Registration batches of cartridge, prefilled-syringe, liquid solution and lyophilized powder products were completed
  - ANDA of 1st prefilled-syringe product - responded to FDA review in Sep. 2021
  - ANDA of 1st liquid solution product - responded to FDA review in Jan. 2022
  - ANDA of 1st lyophilized powder product - submitted to FDA in Dec. 2021
  - Registration batches of 1st cartridge product were completed

Advancing to Injectables

Injectable Plant

- Injectable plant certified by TFDA in Dec. 2021
- FDA's 1st on-site inspection for injectable plant scheduled in Mar. 2022
- Prepare for Injectable CDMO business

China Market

- **3 CFDI on-site inspections completed in Changshu site to facilitate China market growth**

Inspection Date	Product	Approval	Indication	Market
2020.09	Sodium Phenylbutyrate*	2021.05	Urea cycle disorders	Orphan disease medicine
2021.02	Donafenib**	2021.06	Advanced liver cancer first-line treatment	2022 sales projected by research report： c. RMB 400 million
2021.06	Bimatoprost	Expected 2022 Q2	Glaucoma	Prostaglandin drug products c. RMB 1 billion

* Customer's clinic trial for new indication in progress

** Customer summited to NMPA in Oct. 2021 for new indication - Thyroid cancer

- **Changshu site expects to conduct more inspections in 2022**

2022 Product Approval Plan

2022 Product Approval Plan (I)

Type	Product	Region	Indication	Brand Marketer
Generic API	Irinotecan HCl	CN	Colorectal cancer	Pfizer
Generic API	Anastrozole	CN	Breast cancer	ANI Pharmaceuticals
Generic API	Azilsartan	CN	Hypertension	Arbor Pharmaceuticals
Generic API	Bimatoprost	CN	Glaucoma	Allergan
Generic API	Cladribine	CN	Multiple sclerosis	Merck
Generic API	Galantamine HBr	CN	Alzheimer's disease	Janssen
Generic API	Regadenoson	US	MPI	Astellas
Generic API	Topiramate	EU	Weight management	Vivus

2022 Product Approval Plan (II)

Type	Product	Region	Indication	Brand Marketer
Generic Drug	Glatiramer Acetate	US	Multiple sclerosis	Teva
Generic Drug	Pemetrexed 2Na	US	Non-small cell lung cancer	Eli Lilly
Generic Drug	Clofarabine	US	Leukemia	Sanofi
Generic Drug	Bortezomib	US	Multiple myeloma	Takada
CDMO API	Camcevi	EU	Cancer	Foresee
CDMO API	Eflornithine	US/EU	FAP	CPP
CDMO API	Ganaxolone	US	Genetic epilepsy	Marinus
Intermediate for CDMO API	Sotagliflozin	US	Heart failure	Lexicon

Financial Performance

Consolidated Income Statement

NTD Million except for EPS	2021 (Audited)		YoY	2020 (Audited)	
Revenue	2,762	100%	-10%	3,083	100%
Gross Profit	1,280	46%	-3%	1,317	43%
Operating Profit	289	10%	-23%	376	12%
Net Profit before Tax	302	11%	-16%	359	12%
Net Profit after Tax	243	9%	-14%	282	9%
EPS (NTD)	0.31	-	-	0.36	-

2021 Sales Distribution



by Business



by Region



by Indication

ScinoPharm

Sales Distribution – YoY

By Business

Unit: USD

	Generic API	CDMO	Drug Product
2021 Sales	71.9M	14.7M	12.1M
YoY	0.2%	-41.8%	61.0%

By Indication

	Oncology	CNS	Others
2021 Sales	68.4M	22.9M	7.4M
YoY	13.0%	-23.7%	-47.2%

By Region

	US & Canada	EU	Japan	India	China	Others
2021 Sales	27.7M	20.8M	26.1M	8.2M	6.7M	9.2M
YoY	35.8%	-48.6%	33.3%	-32.2%	117.7%	2.6%

Consolidated Balance Sheet

NTD Million	2021/12/31 (Audited)		2020/12/31 (Audited)	
Cash and Cash Equivalents	4,081	35%	4,055	34%
Accounts Receivable	360	3%	387	3%
Inventories	1,345	12%	1,246	11%
Property, Plant & Equipment	4,033	34%	4,211	36%
Other Current/Non-Current Assets	1,872	16%	1,948	16%
Total Assets	**11,691**	**100%**	**11,847**	**100%**
Financial Debt	0	0%	9	0%
Other Current Liabilities	556	5%	677	6%
Other Non-Current Liabilities	624	5%	631	5%
Total Liabilities	**1,180**	**10%**	**1,317**	**11%**
Total Shareholders' Equities	**10,511**	**90%**	**10,530**	**89%**

Consolidated Cash Flow Statement

NTD million	2021 (Audited)	2020 (Audited)
From Operating Activities	510	946
From Investing Activities	(70)	242
From Financing Activities	(413)	(445)
Effect of foreign exchange rate changes	(1)	7
Net Change in Cash	26	750
Beginning Balance	4,055	3,305
Ending Balance	4,081	4,055

Q & A

Appendix

Company Overview

ScinoPharm at a Glance

- Est. in 1997 in Taiwan (Tainan) with cGMP plants/R&D in Tainan and Changshu and marketing forces in Tainan, Shanghai and Tokyo
- Specializes in high potency (cytotoxic/steroid) API and injectable R&D and manufacturing with customers worldwide
- 74 generic APIs in portfolio with 32 referred and approved by ANDA/NDA*
  - 880 active DMFs worldwide with 65 US DMFs*
- 150+ contract projects with 9 approved/launched (7 NCEs) and 6 in phase 3 for NDA/MAA filing in 1-3 years*
- Certified by key international regulators - US FDA, EMA, EDQM, Australian TGA, Japanese PMDA, Korea KFDA, Mexico COFEPRIS and German Authority; certified by TFDA for injectable plant

* Data as of 2022/02/28



Brand Quality with Asian Advantages

www.scinopharm.com

1789 TT